Cyclic GMP (cGMP) has been characterized as a critical, pluripotent second messenger in peripheral tissues. Its effects are particularly important to the regulation of excitable cells such as cardiac and smooth muscle secretory cells. Cyclic GMP also undergoes dramatic fluctuations in the brain in response to excitatory neurotransmission. Recent work has only begun to delineate acute actions of these cGMP elevations on CNS neuronal activity; however, the longterm effects of cGMP on cellular phenotype have been largely unexplored. Preliminary data indicate that cGMP can regulate the activity of transcription factors which bind kB enhancer sequences. Such kB-binding factors have been implicated in control of expression of a diverse array of genes including cell attachment factors, cytokines, and antioxidant enzymes. In addition, several cytokines, as well as cellular oxidation, can activate kB-binding transcription factors. The potential involvement of cytokines in inflammatory brain damage -- and of oxidative insults in a myriad of brain disorders -- has created much interest in the regulation of kB-binding factors in the brain. The studies proposed will test the hypothesis that cGMP can modulate kB- binding factor activity in neuronal cells. Furthermore, these studies will address the possibility that cGMP plays a role in the inductions of kB-dependent transcription effected by several stimuli, including glutamate and cellular oxidation. Specifically, attempts will be made to (1) identify the protein which is induced by cGMP to bind kB enhancers, (2) delineate the mechanistic relationship between cGMP- dependent protein kinase and activity of kB-binding factors, and (3) determine the individual genes activated by cGMP-inducible kB-binding factors in neuronal cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29NS035872-05
Application #
6187389
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Program Officer
Michel, Mary E
Project Start
1996-04-01
Project End
2001-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
5
Fiscal Year
2000
Total Cost
$94,065
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Leroi, Iracema; O'Hearn, Elizabeth; Marsh, Laura et al. (2002) Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. Am J Psychiatry 159:1306-14
Li, Y; Liu, L; Barger, S W et al. (2001) Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res 66:163-70
Li, Y; Barger, S W; Liu, L et al. (2000) S100beta induction of the proinflammatory cytokine interleukin-6 in neurons. J Neurochem 74:143-50
Li, Y; Liu, L; Kang, J et al. (2000) Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 20:149-55
Barger, S W; Chavis, J A; Drew, P D (2000) Dehydroepiandrosterone inhibits microglial nitric oxide production in a stimulus-specific manner. J Neurosci Res 62:503-9
Barger, S W (1999) Complex influence of the L-type calcium-channel agonist BayK8644(+/-) on N-methyl-D-aspartate responses and neuronal survival. Neuroscience 89:101-8
Mao, X; Moerman, A M; Lucas, M M et al. (1999) Inhibition of the activity of a neuronal kappaB-binding factor by glutamate. J Neurochem 73:1851-8
Moerman, A M; Mao, X; Lucas, M M et al. (1999) Characterization of a neuronal kappaB-binding factor distinct from NF-kappaB. Brain Res Mol Brain Res 67:303-15
Mao, X; Barger, S W (1998) Neuroprotection by dehydroepiandrosterone-sulfate: role of an NFkappaB-like factor. Neuroreport 9:759-63